Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.

Garg, Suneel Kumar; Singh, Omender; Juneja, Deven; Tyagi, Niraj; Khurana, Amandeep Singh; Qamra, Amit; Motlekar, Salman; Barkate, Hanmant

Garg, Suneel Kumar; Singh, Omender; Juneja, Deven; Tyagi, Niraj; Khurana, Amandeep Singh; Qamra, Amit; Motlekar, Salman; Barkate, Hanmant.

Afiliación

Garg SK; Institute of Critical Care Medicine, Max Super Specialty Hospital, Saket, New Delhi 110017, India.
Singh O; Institute of Critical Care Medicine, Max Super Specialty Hospital, Saket, New Delhi 110017, India.
Juneja D; Institute of Critical Care Medicine, Max Super Specialty Hospital, Saket, New Delhi 110017, India.
Tyagi N; Department of Critical Care and Emergency Medicine, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi 110060, India.
Khurana AS; Department of Medical Affairs, Wockhardt Ltd., Wockhardt Towers, Mumbai 400051, India.
Qamra A; Department of Medical Affairs, Wockhardt Ltd., Wockhardt Towers, Mumbai 400051, India.
Motlekar S; Department of Medical Affairs, Wockhardt Ltd., Wockhardt Towers, Mumbai 400051, India.
Barkate H; Department of Medical Affairs, Wockhardt Ltd., Wockhardt Towers, Mumbai 400051, India.

Crit Care Res Pract ; 2017: 3635609, 2017.

Article en En | MEDLINE | ID: mdl-28761764

ABSTRACT

ABSTRACT

Polymyxin B has resurged in recent years as a last resort therapy for Gram-negative multidrug-resistant (MDR) and extremely drug resistant (XDR) infections. Understanding newer evidence on polymyxin B is necessary to guide clinical decision making. Here, we present a literature review of polymyxin B in Gram-negative infections with update on its pharmacology.

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Crit Care Res Pract Año: 2017 Tipo del documento: Article País de afiliación: India

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google